Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 312.00
Bid: 312.00
Ask: 314.00
Change: -3.00 (-0.95%)
Spread: 2.00 (0.641%)
Open: 320.00
High: 320.00
Low: 306.50
Prev. Close: 315.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

2 Sep 2015 15:12

RNS Number : 8961X
Oxford Biomedica PLC
02 September 2015
 

 

For filings with the FSA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Oxford Biomedica PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Third National Swedish Pension Fund

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

2015-09-01

6. Date on which issuer notified:

2015-09-02

7. Threshold(s) that is/are crossed orreached: vi, vii

3%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0006648157

78,317,715

78,317,715

77,176,027

77,176,027

2.99%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

77,176,027

2.99%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

15. Contact telephone number:

 

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Third National Swedish Pension Fund

Contact address

(registered office for legal entities)

 

Vasagatan 7, 111 91 Stockholm, Sweden

Phone number & email

 

+468-555 17 100

Other useful information

(at least legal representative for legal persons)

 

Mikael Sedolin

B: Identity of the notifier, if applicable

Full name

 

Sebastian Mossfeldt

Contact address

 

Vasagatan 7, 111 91 Stockholm, Sweden

Phone number & email

 

+468-555 17 162, Sebastian.mossfeldt@ap3.se

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUUASRVRAKRAR
Date   Source Headline
1st Dec 202012:17 pmRNSDirector Dealings
1st Dec 20209:02 amRNSTotal Voting Rights
23rd Nov 20208:47 amRNSOXB notes AZD1222 met primary efficacy endpoint
23rd Nov 20207:00 amRNSNon-Executive Director Appointment
9th Nov 20207:00 amRNSOXB and PhoreMost enter gene therapy collaboration
2nd Nov 20209:02 amRNSTotal Voting Rights
30th Oct 20207:00 amRNSAxovant update on AXO-Lenti-PD and virtual R&D day
23rd Oct 202010:27 amRNSDirector Purchase
12th Oct 20205:38 pmRNSHolding(s) in Company
6th Oct 202012:46 pmRNSAxovant update on 2nd cohort of SUNRISE-PD trial
6th Oct 20207:00 amRNSOXB receives approval for fourth suite in Oxbox
5th Oct 202010:59 amEQSEdison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
2nd Oct 202011:52 amRNSTotal Voting Rights
29th Sep 20203:51 pmRNSDirector Dealings
24th Sep 20209:36 amRNSDirector/PDMR Shareholding
22nd Sep 202012:54 pmRNSDirector/PDMR Shareholding
17th Sep 20207:00 amRNSInterim Results
1st Sep 20209:33 amRNSTotal Voting Rights
1st Sep 20207:00 amRNSMaster Supply and Development Agreement with AZ
27th Aug 20207:00 amRNSNotice of Interim Results
25th Aug 20204:46 pmRNSBlock listing Application
3rd Aug 20209:41 amRNSTotal Voting Rights
3rd Aug 20207:00 amRNSOXB signs DMLA with Beam Therapeutics
31st Jul 20207:00 amRNSOXB Signs Clinical Supply Agreement with Axovant
20th Jul 20204:23 pmRNSOXB notes interim results from AZ on AZD1222
3rd Jul 202010:45 amRNSDirector Dealings / Market Share Purchase
2nd Jul 20203:39 pmRNSDirector Dealings / Market Share Purchase
2nd Jul 20201:34 pmRNSDirector Dealings / Market Share Transactions
1st Jul 20206:30 pmRNSHoldings in Company
1st Jul 20203:44 pmRNSBlock listing Return
1st Jul 20209:13 amRNSTotal Voting Rights
30th Jun 20203:23 pmRNSGrant of options
25th Jun 20209:44 amRNSHolding(s) in Company
24th Jun 202011:45 amRNSHoldings in Company
24th Jun 20209:54 amRNSDirector Dealings / Share Disposal – Replacement
24th Jun 20207:00 amRNSDirector Dealings / Market Share Purchase
23rd Jun 20204:46 pmRNSResult of Annual General Meeting
23rd Jun 20202:47 pmRNSAdmission of shares and Total Voting Rights.
23rd Jun 20207:00 amRNSAnnual General Meeting
19th Jun 20203:26 pmRNSInformation in Relation to Annual General Meeting
19th Jun 20207:00 amRNSResult of Placing
18th Jun 20205:33 pmRNSProposed Placing of new Ordinary Shares
8th Jun 20204:01 pmRNSUpdate on Sanofi Ophthalmology Programmes
8th Jun 20207:00 amRNSFive Year Collaboration Agreement signed with VMIC
1st Jun 20209:06 amRNSTotal Voting Rights
1st Jun 20207:00 amRNSDr Roch Doliveux appointed Non-Executive Chairman
28th May 202012:16 pmRNSClinical & Commercial Supply Agreement with AZ
27th May 202011:26 amRNSDirector Dealings / Market Share Purchase
22nd May 20205:28 pmRNS2019 Annual report and Accounts & AGM Notification
20th May 20202:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.